An announcement from Collegium Pharmaceutical ( (COLL) ) is now available.
On February 27, 2025, Collegium Pharmaceutical reported record financial results for the fourth quarter and full year of 2024, with net revenues reaching $181.9 million for the quarter and $631.4 million for the year. The company achieved a GAAP net income of $12.5 million for the quarter and $69.2 million for the year, alongside a record adjusted EBITDA of $107.7 million for the quarter and $401.2 million for the year. The company also repurchased $60 million in shares in 2024 and reaffirmed its financial guidance for 2025, indicating a strong position for future growth.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on improving the lives of people with serious medical conditions. It has a leading portfolio in responsible pain management medications and has recently expanded into neuropsychiatry with the acquisition of Jornay PM, a treatment for ADHD. The company’s strategy involves growing its commercial portfolio and deploying capital strategically.
YTD Price Performance: -0.98%
Average Trading Volume: 405,844
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $914.3M
Learn more about COLL stock on TipRanks’ Stock Analysis page.